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an heterogeneous cell population with a radio-resistant 
compartment. Evidence to support the use of particle 
therapy evolved in the past 25 years from level III (preclinical 
rationale) to level II (prospective non randomized trials). A 
hot debate has been on-going in the scientific community 
about the need of prospective RCT testing head to head 
particles versus modern X-ray radiotherapy. Those against 
the need of RCT argued that dose distribution was such a 
strong surrogate endpoint that RCT were not needed and that 
dose distribution had always guided the evolution of 
radiotherapy without the need of RCT. Those in favour 
argued that the only relevant endpoints were clinical 
outcome and measurable toxicity and that dose distributions 
of protontherapy despite its unquestionable advantage in 
terms of integral dose may be in some case less favourable 
than advanced x-ray dose distribution because of lateral 
scattering and shallower dose gradients in the high dose 
region. Historically only a single RCT of particle versus 
photons has been conducted, namely the UCSF-LBNL trial 
comparing helium ions radiotherapy versus Iodine-125 plaque 
brachytherapy for choroidal and ciliary body melanoma . 
Long terms result of the trial a showed a clear advantage of 
charged particles over brachytherapy in terms of local 
control. However this result did not definitively solve the 
issue as helium is no longer used in clinical practice and 
extrapolation of this trial to protontherapy is maybe not 
straightforward; moreover the trial was criticized because of 
a supposed suboptimal technique in the brachytherapy arm. 
With the increased availability of proton facilities the amount 
of non-randomized evidence is rapidly increasing and several 
prospective non-randomized trial are being conducted. At 
present particle therapy has found its way in several 
guidelines. As an example in the last version of ESMO 
guidelines for bone sarcoma particle therapy is considered 
the first option for chordoma both in the post operative 
setting and for inoperable disease. In this framework also 
RCT are at present being conducted. A prospective phase II 
RCT in stage II-IIB NSCLC patients (NCT00915005) randomized 
to either photons or protons adaptive IGRT with two levels of 
dose (66 Gy [RBE] + vs. 74 Gy [RBE]) with primary endpoints 
local control and toxicity G≥3 has completed its accrual. Two 
other trials are testing protontherapy vs photons X-Ray in 
locally advanced NSCLC (RTOG 1308) or in centrally located 
stage I NSCLC (NCT01511081) and are expected to complete 
accrual in 2020 and 2016. Another prospective phase III RCT 
ongoing at MGH testing IMRT vs protontherapy for prostate 
cancer (NCT01617161) is expected to complete accrual in 
2016 A prospective phase II/III RCT for stage III and IV 
oropharyngeal SCC (NCT01893307) is comparing 70 Gy [RBE] 
delivered with either IMRT or intensity modulated 
protontherapy. And is expected to complete accrual by 2023 
Another trial is testing protons vs photons in GBM 
(NCT01854554) and should complete accrual by 2017. A RCT 
is recruiting patient with oesophageal cancer to test chemo 
radiation with photons vs. chemo radiation with protons 
(NCT01512589) and should be completed within 2018. Other 
RCT are ongoing comparing protons versus carbon ions in 
sacral chordoma (ISAC trial NCT01811394) in skull base 
chordoma (NCT01182779) and in skull base chondrosarcoma 
(NCT01182753). RCT are recruiting patient to test 
protontherapy vs RF ablation in HCC (NCT01963429) or 
protontherapy + sorafenib vs. sorafenib alone in HCC 
(NCT01141478). A RCT of particle therapy vs surgery for 
sacral chordoma (SACRO) is in its final design stage in Europe. 
Another phase III RCT of carbon ion radiotherapy versus 
photons or protons radiotherapy for head and neck soft tissue 
sarcoma and adenoid cystic carcinoma (PHRC ETOILE-ULICE) 
is going to start recruitment in the next year. In conclusion 
the present day clinical evidence for particle therapy is of 
level II (with the only exception of eye melanoma). A large 
effort to produce level I evidence is ongoing worldwide. 
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Purpose or Objective: This study evaluates 
FTY720/Fingolimod as a potential mitigator of radiation-
induced neurocognitive dysfunction. 
 
Material and Methods: The effects of radiation and FTY720 
on neural progenitor cells (NPCs) and brain tumor stem cells 
(BTSCs) were tested in vitro. To study radiation-induced 
neurocognitive deficits, 6 week-old C57/Bl/6J mice received 
0 or 7 Gy cranial irradiation and were treated with 
intraperitoneal FTY720 or vehicle for seven weeks. Fear 
conditioning and the Morris water maze were then employed 
to test learning and memory. Immunohistochemical staining 
for NPCs and mature neurons was used to assess changes in 
neurogenesis. To test effects on tumor growth, mice 
harboring BTSC xenografts were treated with intraperitoneal 
FTY720 or vehicle for six weeks. 
 
Results: In NPCs, FTY720 induced ERK1/2 phosphorylation in 
the presence of radiation. In glioma cells, ERK1/2 
phosphorylation was detected at baseline, and FTY720 did 
not elicit any further increase. Correspondingly, FTY720 
increased the viability of NSCs but not glioma cells after 
radiation. Inhibiting S1P1/MAPK signaling in NPCs abolished 
the protective effects of FTY720. In irradiated mice, learning 
deficits were manifested by significantly longer latency times 
compared to non-irradiated controls (p = 0.001). The deficits 
were fully restored by FTY720. In irradiated brains, FTY720 
maintained a viable NPC pool and restored the 
cytoarchitecture of the DG granular cell layer. In mice 
harboring BTSC xenografts FTY720 delayed tumor growth and 
improved survival (p=0.012). 
 
Conclusion: FTY720 mitigates radiation-induced learning 
dysfunction by partially restoring DG neurogenesis. 
Furthermore, FTY720 appears to delay tumor growth and 
improve survival in a xenograft glioma mouse model.  
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Purpose or Objective: Radiation therapy is a mainstay for 
lung cancer therapy, but the effective dose is commonly 
limited by the onset of radiation-induced lung damage. Single 
pathway inhibitors against transforming growth factor β 
(TGFβ), platelet-derived growth factor (PDGF) and others 
have been shown in experimental models to attenuate 
radiation-induced pulmonary injury. However, the effects of 
multiple pathway inhibition regarding the development of 
these diseases remain unknown. 
 
Material and Methods: C57BL/6 mice were treated with a 
single dose of up to 20 Gy photons to their thoraxt o induce 
radiation induced lung toxicity. After Irradiation , small 
